The capital of Sweden possesses not only world-renowned academic research and high profile life science companies, it is also home to many of the country’s most important national life science efforts and leading centers. The
Nordic Life Science
Nordic Life Science
The latest business news
Yesterday, the Confederation of Swedish Enterprise (Svenskt Näringsliv) held a press conference where they presented Jan Olof Jacke as their new CEO. “Swedish Enterprise has a central role as representative
The company expands its inhalation capabilities with GBP 45 million acquisition of Sanofi CMO business located in UK. The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel,
She has been called the Danish biotech queen and she is not afraid of responsibility in her role as CEO, currently at Zealand Pharma. On the contrary, Britt Meelby Jensen
The recent growth of the country’s life science industry is for example demonstrated in a new report by the Swedish Agency for Growth Policy Analysis and the fast growth of
The money will be used to develop a computer program that can predict how the immune system will react to different substances, reports the company. Today, Immunitrack is offering contracted
Advertising
Drug & Device development
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for
H. Lundbeck A/S and Takeda Pharmaceutical announce positive results from their pivotal study with vortioxetine in adults with Major Depressive Disorder conducted in Japan. Both companies intend to move forward
The US Food & Drug Administration has granted Fast Track designation to Betalutin (177Lu-lilotomab satetraxetan) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least
Lundbeck and Otsuka Pharmaceutical announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on Rxulti (brexpiprazole) for
The company has anounced results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1
The two pharma giants reports data which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of
Abcam and Shuwen Biotech sign strategic MoU to establish global alliance for companion diagnostic (CDx) kit development 18 June 2018 by Abcam
The capital of Sweden possesses not only world-renowned academic research and high profile life science companies, it is also home to many of the country’s most important national life science efforts and leading centers. The
Advertising
Latest news
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for
Abcam and Shuwen Biotech sign strategic MoU to establish global alliance for companion diagnostic (CDx) kit development 18 June 2018 by Abcam
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for
H. Lundbeck A/S and Takeda Pharmaceutical announce positive results from their pivotal study with vortioxetine in adults with Major Depressive Disorder conducted in Japan. Both companies intend to move forward
Lundbeck and Otsuka Pharmaceutical announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on Rxulti (brexpiprazole) for
The company has anounced results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1
The two pharma giants reports data which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of
The Phase 2b trial with Betalutin (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional Committees for Medical and Health Research Ethics (REK) in Norway.
The trial, the second of two pivotal Phase III trials for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), did not meet the primary endpoint of
All subjects have been enrolled and dosed in the second and pivotal Phase 3 trial to confirm the clinical efficacy and safety of dasiglucagon for the rescue treatment of severe
The company has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase
The latest research findings from the Nordic region
Science Article
A new study from Karolinska Institutet and the University of Helsinki show that therapeutic use of gene editing with the CRISPR-Cas9 technique may inadvertently increase the risk of cancer. Two
A network for the promotion of research and education in microfluidics was recently launched at a conference at SciLifeLab. Microfluidics is a research area that deals with fluids on the
On May 28th international scientists and experts within outcomes research and patient centred healthcare gathered at the Karolinska Institute to discuss patient-driven development of pharmaceuticals, Swedish quality registers and their
High activity in a relatively poorly studied group of brain cells can be linked to aggressive behaviour in mice, a new study from Karolinska Institutet in Sweden shows. Using optogenetic
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. Genetic studies have linked
Researchers at Karolinska Institutet have developed a new disease model for neurodegenerative diseases such as ALS and MS that can be used to develop new immunotherapies. In a healthy brain,
